Relief Therapeutics and Acer Therapeutics Sign Option Agreement for Exclusivity to Negotiate a Collaboration and License Agreement for the Worldwide Development and Commercialization of ACER-001 for the Treatment of Urea Cycle Disorders and Maple Syrup Urine Disease

NEXT STORY
Chiesi USA, Inc. Receives Top Employer in the U.S. Certification for 2021
PREV STORY
Republic First Bancorp, Inc. Reports Fourth Quarter Financial Results Deposits Grow 34% and Earnings Continue to Improve as Momentum Builds
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Resverlogix Enters into a Cooperation Agreement with the Supreme Council of the Arab-African Economy to Support the Development of Apabetalone for COVID-19 Patients

author_avatar
NASDAQ Market News

Cempra to Report Third Quarter 2016 Financial Results

CHAPEL HILL, N.C., Oct. 25, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage ...

author_avatar
NASDAQ Market News

Relay Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

author_avatar
NASDAQ Market News